3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Paclitaxel
292
Gemcitabine
254
Carboplatin
254
Cisplatin
251
Radiotherapy
219
Cyclophosphamide
218
Irinotecan
184
pembrolizumab
181
Docetaxel
174
Bevacizumab
166
Capecitabine
148
Nivolumab
141
Fluorouracil
132
Dexamethasone
125
Bortezomib
123
Oxaliplatin
115
Cytarabine
113
Erlotinib Hydrochloride
112
Temozolomide
110
Sorafenib
110
Doxorubicin
106
Rituximab
105
Leucovorin
105
Etoposide
105
Filgrastim
99
Everolimus
97
Lenalidomide
95
Pemetrexed
90
Ipilimumab
90
fludarabine phosphate
84
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Completed
×
Oncolytic Virotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled